Mapmygenome partners with Lucid Diagnostics to offer ‘DNA Onco Screen’ for cancer screening

DNA Onco Screen assesses genetic predisposition to various cancers, physiological traits known to trigger cancer, and lifestyle traits linked to cancer risk. Key clinical markers associated with cancer are also tested

0
86
Download PDF

Hyderabad: Lucid Diagnostics, a premier diagnostics company and Mapmygenome, a molecular diagnostics company, have announced their alliance to advance cutting-edge, personalized and preventive medicine by combining genomics and pathology lab services. Lucid will offer DNA Onco Screen™ to customers and physicians for prevention and early detection of cancers.

“Genetics is an important part of clinical diagnostics and we are pleased to offer these packages with Mapmygenome,” said Dr Sunitha Lingareddy, Managing Director, Lucid Diagnostics.

“We are quite excited about this partnership,” said Ms Anu Acharya, CEO, Mapmygenome. “Combining clinical parameters with genomics makes it very compelling for physicians and consumers to get a comprehensive screen.”

DNA Onco Screen assesses genetic predisposition to various cancers, physiological traits known to trigger cancer, and lifestyle traits linked to cancer risk. Key clinical markers associated with cancer are also tested.  Also offered are advanced packages for men and women, with a complete assessment by the doctor. All packages include genetic counselling to help understand individuals’ risk of cancer, inheritance patterns, and lifestyle changes essential to prevent cancer. These packages are the most effective, efficient, and comprehensive cancer screening tests available in the country.